DRUG DISCOVERY AND DEVELOPMENT
for unmet need in oncology and pulmonary fibrosis
MD2 Biosciences is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics in the area of oncology. We are pursuing product candidates with a strong scientific rationale to address a high unmet need in oncology and an opportunity to develop best-in-class or first-in-class programs. To accomplish this goal, we have assembled an experienced and highly skilled group of scientists, key opinion leaders from leading academic centers, and biotechnology and pharmaceutical companies. Our goal is to enhance and extend patients' lives suffering from various cancers.
in drug discovery and Optimization
MD2 Biosciences uses artificial intelligence (AI) in drug discovery and optimization
Our scientists developed a novel platform to identify small-molecule hits suitable for flat proteins. Our methodology predicts potential hotspots of the target protein and assigns a protein-ligand specificity index, which can be extremely helpful during the lead generation stage. Coupled with medicinal chemistry design expertise and using modern drug discovery property predictors, our AI platform further supports the lead optimization process. Using our AI, we successfully generated novel lead compounds with suitable properties for the intended route of administration (oral or IV, etc.) and CNS delivery by allowing drug molecules to cross the blood-brain barrier (BBB).